神经影像学
阿尔茨海默病神经影像学倡议
疾病
生物标志物
临床试验
医学
心理学
肿瘤科
神经科学
阿尔茨海默病
内科学
生物
生物化学
作者
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Charles DeCarli,Robert Green,Danielle Harvey,Clifford R. Jack,William J. Jagust,Susan Landau,John C. Morris,Ozioma C. Okonkwo,Richard J. Perrin,Ronald C. Petersen,Monica Rivera‐Mindt,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,Duygu Tosun,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative
摘要
Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. Methods We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. Results Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. Discussion ADNI has had a profound impact in improving clinical trials for AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI